Recent News

• 08.05.2026 - Grace Therapeutics Announces $10 Million Private Placement
• 07.28.2026 - Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
• 06.18.2026 - Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
• 04.23.2026 - Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
• 04.14.2026 - Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
• 03.19.2026 - Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
• 02.25.2026 - Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
• 02.12.2026 - Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
• 11.17.2025 - Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference
• 11.13.2025 - Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Recent Filings

• 07.28.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 07.28.2026 - DEF 14A Other definitive proxy statements
• 07.28.2026 - 8-K Current report
• 07.28.2026 - EX-99.1 EX-99.1
• 06.18.2026 - 8-K Current report
• 06.18.2026 - EX-99.1 EX-99.1
• 06.18.2026 - 8-K Current report
• 06.18.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 06.18.2026 - EX-99.1 EX-99.1
• 06.05.2026 - 8-K Current report